Researchers from The University of Texas MD Anderson Cancer Center demonstrated that anti-PD-L1 immunotherapy in combination with mutation-directed targeted therapy extended overall survival (OS) in patients with anaplastic thyroid carcinoma (ATC). Findings from the Phase II single center study published today in JAMA Oncology.

Researchers have discovered key mutations in certain cancer cells that make them resistant to WRN inhibitors, a new class of anti-cancer drugs.

Patients with advanced bladder cancer that had spread to other parts of the body (metastasized) have responded well in a phase I clinical trial of an investigational drug, TYRA-300.

What keeps some immune systems youthful and effective in warding off age-related diseases? In a new paper published in Cellular & Molecular Immunology, USC Stem Cell scientist Rong Lu and her collaborators point the finger at a small subset of blood stem cells, which make an outsized contribution to maintaining either a youthful balance or an age-related imbalance of the two main types of immune cells: innate and adaptive.

Researcher sassess the positive impact of aerobic exercise during chemotherapy on cognitive function.

Drugs designed to target HER2-postive breast cancer could also benefit some patients with bile duct cancer, according to results of a patient trial to be presented on Thursday at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain.